1-7 of 7
Pedro Dorlhiac-Llacer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Nilotinib Shows Safety and Efficacy in Older Patients (≥ 65 years) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Comparable with That in Younger Patients with Chronic Myeloid Leukemia in Chronic Phase: Results From ENESTnd,

Richard A. Larson, MD, Udomsak Bunworasate, MD, Anna G. Turkina, MD, PhD, Stuart L. Goldberg, MD, Pedro Dorlhiac-Llacer, MD, Jose L. Lopez, MD, Hagop M. Kantarjian, Giuseppe Saglio, MD, Andreas Hochhaus, MD, Albert Hoenekopp, MD, Rick E. Blakesley, PhD, Richard Yu, Neil J. Gallagher, MD, PhD, Richard E. Clark, MD, Timothy P. Hughes, MD, MBBS
Journal: Blood
Blood (2011) 118 (21): 3768.
https://doi.org/10.1182/blood.V118.21.3768.3768
Published: 2011
Journal Articles

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

Clinical Trials & Observations
Hagop Kantarjian, Jorge Cortes, Dong-Wook Kim, Pedro Dorlhiac-Llacer, Ricardo Pasquini, John DiPersio, Martin C. Müller, Jerald P. Radich, H. Jean Khoury, Nina Khoroshko, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman
Journal: Blood
Blood (2009) 113 (25): 6322–6329.
https://doi.org/10.1182/blood-2008-11-186817
Published: 2009
Journal Articles

Myelodysplasia and Acute Myeloid Leukemia during Treatment of Chronic Myeloid Leukemia with Dasatinib

Monika Conchon, Israel Bendit, Patricia Ferreira, Lucia Dias, Cristina Kumeda, Dalton Chamone, Pedro Dorlhiac-Llacer
Journal: Blood
Blood (2008) 112 (11): 4284.
https://doi.org/10.1182/blood.V112.11.4284.4284
Published: 2008
Journal Articles

Dasatinib 140 Mg Once Daily (QD) Demonstrates Equivalent Efficacy and Improved Safety Compared with 70 Mg Twice Daily (BID) in Patients with Accelerated Phase Chronic Myeloid Leukemia (CML-AP): 2-Year Follow-up Data from CA180-035

Hagop M. Kantarjian, MD, Dong-Wook Kim, MD, PhD, Pedro Dorlhiac-Llacer, Ricardo Pasquini, Nina Khoroshko, John F. DiPersio, MD, PhD, Martin C Müller, MD, M. Brigid Bradley-Garelik, Chao Zhu, Martin S. Tallman, MD
Journal: Blood
Blood (2008) 112 (11): 3224.
https://doi.org/10.1182/blood.V112.11.3224.3224
Published: 2008
Journal Articles

Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose

Neil P. Shah, MD, PhD, Dong-Wook Kim, MD, PhD, Hagop M. Kantarjian, MD, Philippe Rousselot, MD, PhD, Pedro Dorlhiac-Llacer, Jorge Milone, MD, Martin C Müller, MD, Yousif Matloub, Alexandre Lambert, Andreas Hochhaus, MD
Journal: Blood
Blood (2008) 112 (11): 3225.
https://doi.org/10.1182/blood.V112.11.3225.3225
Published: 2008
Journal Articles

Outpatient Treatment with Intravenous Antimicrobial Therapy in Patients with Febrile Neutropenia and Hematologic Malignancies

Marcelo Bellesso, Luis Fernando Pracchia, Lucia Dias, Dalton Chamone, Pedro Dorlhiac-Llacer
Journal: Blood
Blood (2008) 112 (11): 4717.
https://doi.org/10.1182/blood.V112.11.4717.4717
Published: 2008
Journal Articles

Cost-Effectiveness of Imatinib Versus Interferon-α in the Treatment of Patients Newly Diagnosed with Chronic Myeloid Leukemia, under the Brazilian Public Healthcare System Perspective.

Fábio Mataveli, MD, MBA, Alessandra Calabró, MBA, Wellington Mendes, MD, Denizar Vianna, MD,PhD, Pedro Dorlhiac-Llacer, MD,PhD, Ricardo Bigni, MD,PhD, Vania Hungria, MD,PhD
Journal: Blood
Blood (2006) 108 (11): 3314.
https://doi.org/10.1182/blood.V108.11.3314.3314
Published: 2006